1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3
2 Introduction 4
2.1 Gastric Cancer Market 4
2.2 Gastric Cancer Disease 4
2.3 Market Forecasts Report Guidance 6
3 Gastric Cancer Disease Market: Market Characterization 7
3.1 Gastric Cancer Disease Market 7
3.2 Gastric Cancer Disease Market Forecast and CAGR 7
3.3 Drivers for the Gastric Cancer Disease Market 7
3.3.1 High Incidence 8
3.3.2 High Prevalence 8
3.3.3 Low Initial Diagnosis Rate 8
3.3.4 High Mortality Rate 9
4 Tumor Node Metastases (TNM) Classification of Gastric Cancer 10
5 Xeloda 13
5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Studies 13
5.4 Sales Drivers 14
5.4.1 Gastric Cancer Market 14
5.4.2 Absence of Competition in The US and EU 14
5.4.3 Oral Administration 14
5.4.4 Cost of Xeloda in Japan 14
5.5 Drug Risk Benefit Score 15
5.5.1 Efficacy 15
5.5.2 Safety 15
5.5.3 Compliance 15
5.5.4 Dosing Convenience 15
5.6 Intensity of Competition 16
5.7 Sales forecast 16
5.7.1 Target patient Pool of Xeloda 16
5.7.2 Dosing 17
5.7.3 Market Penetration 18
5.7.4 Annual Cost of Therapy 18
5.7.5 Sales Projection of Xeloda 18
6 Gastric Cancer Market: Appendix 22
6.1 Market Definitions 22
6.2 List of Abberiviations 23
6.3 Research Methodology 23
6.3.1 Coverage 23
6.3.2 Secondary Research 23
6.3.3 Forecasting 23
6.3.4 Number of Patients Approved to take the Drug 24
6.3.5 Net Penetration of Drug 24
6.3.6 Net Annual Dosing 24
6.3.7 Annual Cost of Therapy 24
6.3.8 Primary Research 24
6.3.9 Expert Panels 24
6.4 Contact Us 24
6.5 Disclaimer 24
6.6 Sources 24
1.1 List of Tables
Table 1: Gastric Cancer Incidence and Mortality,2008–2030 5
Table 2: Gastric Cancer, Estimated Global Market ($bn),2009–2020 7
Table 3: Overall Survival Results 13
Table 4: Results of Second Phase III Trial 14
Table 5: Drug Risk Benefit Score of Xeloda 15
Table 6: Annual Cost of Therapy of Xeloda, The US 18
Table 7: Gastric Cancer, The US,EU-5 and Japan, Estimated Sales of Xeloda($m),2007–2020 19
Table 8: Gastric Cancer, The US, Estimated Sales of Xeloda($m),2012–2020 20
Table 9: Gastric Cancer,EU-5, Estimated Sales of Xeloda($m),2007–2020 21
Table 10: Gastric Cancer, Japan, Estimated Sales of Xeloda($m),2011–2020 22
1.2 List of Figures
Figure 1: Percentage Distribution of the Top 20 Cancers 4
Figure 2: Fatality =[(%Distribution of Incidence)-(%Distribution of Mortality)] of the Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption Curve, the US,1976-2006 6
Figure 4: Estimated Global Gastric Cancer Market,2009–2020 7
Figure 5: Oncology,Global,Incidence(in million),2008–2030 8
Figure 6: Gastric Cancer, Global, Incidence(in million),2008–2030 8
Figure 7: Broad Classification of Gastric Cancer in the US and EU 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of Gastric Cancer in the US and EU-5 12
Figure 11: Classification of Gastric Cancer in Japan 12
Figure 12: Drug Model Diagram of Xeloda in the US and EU 16
Figure 13: Drug Model Diagram of Xeloda in Japan 17
Figure 14: Gastric Cancer, The US,EU-5 and Japan, Estimated Sales of Xeloda ($m),2007–2020 19
Figure 15: Gastric Cancer, The US, Estimated Sales of Xeloda($m),2012-2020 20
Figure 16: Gastric Cancer, EU-5, Estimated Sales of Xeloda($m),2007-2020 21
Figure 17: Gastric Cancer, Japan, Estimated Sales Forecast of Xeloda($m),2011-2020 22
NO:12-12
設為首頁 
關于市場調查網
